A Unique Candlelight Concert in the Middle of the Desert Set in the Exclusive Location of the Archaeological Site of Hegra, the UNESCO World Heritage Site
A new magical experience has just lit up in the middle of the desert. People could live a unique emotion by attending the Candlelight Concert, an atmospheric musical performance set in the archaeological site of Hegra (AlUla, Saudi Arabia), the UNESCO World Heritage Site famous for having more than 100 monumental tombs carved from rock formations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005155/en/
Hegra Candlelight Classic ph.Emad Alhusayni Balich Wonder Studio
The archaeological site, just 22 minutes far from the city of AlUla, has never been used for concerts of such intimate character.
The first concert that took place on the 24th December 2021 and the next one that will take place on the 31st December 2021 are produced by Balich Wonder Studio , the live entertainment group, leader in the creation and production of large-scale ceremonies, events and shows, brand and territorial experiences worldwide.
The audience live a full emotional experience by listening to the evocative repertoire performed live by the Stefan Lombard ensemble (piano, violin, cello and oud). The famous South African musical Director has created a suite (a collection of short musical pieces) from classic compositions to contemporary, Arab, movie soundtracks and a revised take on pop music.
More than 500 high-tech candles are the magic surrounding of these musical performances: sculpted by hand, they allow spectacular graphic patterns that emotionally enhance the special moments by blending harmoniously with the forms of the archaeological site, creating a landmark that merges the suggestions of the past and the dynamic of the contemporary.
The events exploit the latest technologies as the candles thanks to their various control possibilities, can shine all night, cozily shaping the surrounding and could reach four times the brightness of a traditional candle without burning or melting: the unique color combination allows for the same warmth as a real flame candle. In addition, its innovative algorithm can make an entire set of candles flicker differently, just like real candles would.
These two special events are exclusive occasions within the suggestive AlUla Moments Season, specifically designed for ‘Winter At Tantora’. The whole season is filled with high-end cultural, musical, wellness and arts events, as well as star-studded concerts, adventurous activities and immersive heritage experiences. BWS-KSA, the branch of the Balich Wonder Studio group based in Saudi Arabia, has been appointed by the Royal Commission for AlUla to produce multiple activities throughout the entire season that will enfold in late March.
The area and the city of AlJadidah has become an exclusive gathering spot, divided in various hubs where different cultures from all over the world, itinerant performing artists and the best of the circus arts will mix and mingle in the spirit of nomadic culture and the traditional Saudi Arabian hospitality with the aim to attract the widest audience and be inclusive.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005155/en/
Contact information
Balich Wonder Studio
Elettra Zadra
elettra.zadra@balichws.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom